The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound — is officially over.
This Popular Weight Loss Drug Can Now Be Used To Treat Sleep Apnea
Zepbound is the first medication approved to treat people with obstructive sleep apnea, said Sailly Seymor, director of FDA's division of pulmonology, allergy, and critical care.
FDA Approves Zepbound for Obstructive Sleep Apnea
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
KSL15h
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
Zepbound and Lilly's widely used diabetes drug, Mounjaro, both chemically called tirzepatide, belong to a class of drugs ...
rheumatologyadvisor15d
Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
ABC News23d
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Tirzepatide, used in Zepbound and Mounjaro ... the idea that dual mechanisms of action will producer greater weight loss," Aronne, also the Sanford I. Weill Professor of Metabolic Research ...
Medical News Today17d
Average weight loss on Zepbound
Research consistently suggests people with overweight or obesity have more average weight loss on Zepbound than a placebo. The active ingredient in Zepbound is tirzepatide, which falls into ...
Time22d
Which Weight-Loss Drug Is Better: Wegovy or Zepbound?
Wegovy (semaglutide) and Zepbound (tirzepatide) both target a group ... was linked to more weight loss than Wegovy, but until now, no studies have compared the two medications directly.
ABC News19d
Zepbound users discuss weight loss after preliminary research touts effectiveness
Zepbound is a medication containing tirzepatide, which the preliminary study showed to be more effective for weight loss than Wegovy, which contains semaglutide. This preliminary study ...
FOX59 News22d
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Zepbound ® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% ...